NOBRE, L., M. ZAPOTOCKY, S. KHAN, K. FUKUOKA, A. FONSECA, T. MCKEOWN, D. SUMERAUER, A. VICHA, W. A. GRAJKOWSKA, J. TRUBICKA, K. K. W. LI, H. K. NG, L. MASSIMI, J. Y. LEE, S. K. KIM, S. ZELCER, A. VASILJEVIC, C. FAURE-CONTER, P. HAUSER, B. LACH, M. L. VAN VEELEN-VINCENT, PJ FRENCH, Meir EG VAN, W. A. WEISS, N. GUPTA, I. F. POLLACK, R. L. HAMILTON, A. A. N. RAO, C. GIANNINI, J. B. RUBIN, A. S. MOORE, L. B. CHAMBLESS, R. VIBHAKAR, Y. S. RA, M. MASSIMINO, R. E. MCLENDON, H. WHEELER, M. ZOLLO, V. FERRUCI, T. KUMABE, C. C. FARIA, Jaroslav ŠTĚRBA, S. JUNG, E. LOPEZ-AGUILAR, J. MORA, C. G. CARLOTTI, J. M. OLSON, S. LEARY, J. CAIN, L. KRSKOVA, J. ZAMECNIK, C. E. HAWKINS, U. TABORI, A. N. HUANG, U. BARTELS, P. A. NORTHCOTT, M. D. TAYLOR, S. YIP, J. R. HANSFORD, E. BOUFFET and V. RAMASWAMY. Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. CELL REPORTS MEDICINE. AMSTERDAM: ELSEVIER, 2020, vol. 1, No 3, p. 1-11. ISSN 2666-3791. Available from: https://dx.doi.org/10.1016/j.xcrm.2020.100038.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma
Authors NOBRE, L., M. ZAPOTOCKY, S. KHAN, K. FUKUOKA, A. FONSECA, T. MCKEOWN, D. SUMERAUER, A. VICHA, W. A. GRAJKOWSKA, J. TRUBICKA, K. K. W. LI, H. K. NG, L. MASSIMI, J. Y. LEE, S. K. KIM, S. ZELCER, A. VASILJEVIC, C. FAURE-CONTER, P. HAUSER, B. LACH, M. L. VAN VEELEN-VINCENT, PJ FRENCH, Meir EG VAN, W. A. WEISS, N. GUPTA, I. F. POLLACK, R. L. HAMILTON, A. A. N. RAO, C. GIANNINI, J. B. RUBIN, A. S. MOORE, L. B. CHAMBLESS, R. VIBHAKAR, Y. S. RA, M. MASSIMINO, R. E. MCLENDON, H. WHEELER, M. ZOLLO, V. FERRUCI, T. KUMABE, C. C. FARIA, Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), S. JUNG, E. LOPEZ-AGUILAR, J. MORA, C. G. CARLOTTI, J. M. OLSON, S. LEARY, J. CAIN, L. KRSKOVA, J. ZAMECNIK, C. E. HAWKINS, U. TABORI, A. N. HUANG, U. BARTELS, P. A. NORTHCOTT, M. D. TAYLOR, S. YIP, J. R. HANSFORD, E. BOUFFET and V. RAMASWAMY (guarantor).
Edition CELL REPORTS MEDICINE, AMSTERDAM, ELSEVIER, 2020, 2666-3791.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10601 Cell biology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/20:00118572
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.xcrm.2020.100038
UT WoS 000642296600006
Keywords in English WNT-Activated Medulloblastoma
Tags 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 6/5/2021 07:51.
Abstract
Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763-0.925) with 15 relapsed individuals identified. Maintenance chemotherapy is identified as a strong predictor of relapse, with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molecularly confirmed relapse (p = 0.032). The anatomical location of recurrence is metastatic in 12 of 15 relapses, with 8 of 12 metastatic relapses in the lateral ventricles. Maintenance chemotherapy, specifically cumulative cyclophosphamide doses, is a significant predictor of relapse across WNT MB. Future efforts to de-escalate therapy need to carefully consider not only the radiation dose but also the chemotherapy regimen and the propensity for metastatic relapses.
PrintDisplayed: 18/8/2024 05:38